Mobile

A study, in which patients with late stage lung cancer and changes in a gene called EGFR, will be first treated for 8 weeks with the drug erlotinib and if they have clinical benfit will receive either...

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-005476-33

A study, in which patients with late stage lung cancer and changes in a gene called EGFR, will be first treated for 8 weeks with the drug erlotinib and if they have clinical benfit will receive either a combination of an experimental drug called LY2875358 plus erlotinib or erlotinib alone

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to compare PFS of LY2875358 plus erlotinib therapy with erlotinib monotherapy as first-line treatment in metastatic NSCLC patients with activating EGFRmt who have disease control after an 8-week lead-in treatment with erlotinib monotherapy.

Critère d'inclusion

  • non-small cell lung cancer

Liens